DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome
The SGLT2 inhibitor dapagliflozin provided significant and clinically meaningful reductions in heart failure outcomes, according to the sponsoring company.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news